Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors

The purpose of this study was to retrospectively review the pathologic complete response (pCR) rate from patients (n=86) with stage II and III HER2-positive breast cancer treated with neoadjuvant chemotherapy at our institution from 2008 to 2013 and to determine possible predictive and prognostic fa...

Descripción completa

Detalles Bibliográficos
Autores principales: Buzatto, I.P.C., Ribeiro-Silva, A., Andrade, J.M., Carrara, H.H.A., Silveira, W.A., Tiezzi, D.G.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Associação Brasileira de Divulgação Científica 2017
Materias:
Clinical Investigation
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304215/
https://www.ncbi.nlm.nih.gov/pubmed/28146217
http://dx.doi.org/10.1590/1414-431X20165674

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5304215/
https://www.ncbi.nlm.nih.gov/pubmed/28146217
http://dx.doi.org/10.1590/1414-431X20165674

Ejemplares similares